Summary
The purpose of the present study was to examine the effects of oxidative stress on ventricular arrhythmias in rabbits with adriamycin-induced cardiomyopathy and the relationship between oxidative stress and ventricular arrhythmia. Forty Japanese white rabbits were randomly divided into four groups (n=10 in each): control group, metoprolol (a selective β1 receptor blocker) group, carvedilol (a nonselective β blocker/α-1 blocker) group and adriamycin group. Models of adriamycin-induced cardiomyopathy were established by intravenously injecting adriamycin hydrochloride (1 mg/kg) to rabbits via the auri-edge vein twice a week for 8 weeks in the adriamycin, metoprolol and carvedilol groups. Rabbits in the control group were given equal volume of saline through the auri-edge vein. Rabbits in the metoprolol and carvedilol groups were then intragastrically administrated metoprolol (5 mg/kg/d) and carvedilol (5 mg/kg/d) respectively for 2 months, while those in the adriamycin and control groups were treated with equal volume of saline in the same manner as in the metroprolol and carvedilol groups. Left ventricular end diastolic diameter (LVEDd) and left ventricular ejection fraction (LVEF) were measured by echocardiography. Plasma levels of N-terminal pro B-type natriuretic peptide (NT-proBNP), malondialdehyde (MAD) and superoxide dismutase (SOD) were detected. The left ventricular wedge preparations were perfused with Tyrode’s solution. The transmural electrocardiogram, transmural action potentials from epicardium (Epi) and endocardium (Endo), transmural repolarization dispersion (TDR) were recorded, and the incidences of triggered activity and ventricular arrhythmias were obtained at rapid cycle lengths. The results showed that TDR and the serum MDA and NT-proBNP levels were increased, and LVEF and the serum SOD level decreased in the adriamycin group compared with the control group. The incidences of triggered activity and ventricular arrhythmia were significantly higher in the adriamycin group than those in the control group (P<0.05). In the carvedilol group as compared with the adriamycin group, the serum SOD level and the LVEF were substantially increased; the TDR, and the serum MDA and NT-proBNP levels were significantly decreased; the incidences of triggered activity and ventricular arrhythmia were obviously reduced (P<0.05). There were no significant differences in the levels of MDA and SOD, LVEF, TDR and the incidences of triggered activity and ventricular arrhythmia between the adriamycin group and the metoprolol group. It was concluded that carvedilol may inhibit triggered activity and ventricular arrhythmias in rabbit with adriamycin-induced cardiomyopathy, which is related to the decrease in oxygen free radials.
Similar content being viewed by others
References
Chatterjee K, Zhang J, Honbo N, et al. Doxorubicin cardiomyopathy. Cardiology, 2010,115(2):155–162
Ludke AR, Al-Shudiefat AA, Dhingra S, et al. Singal PKA concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity. Can J Physiol Pharmacol, 2009,87(10):756–763
Chaiswing L, Cole MP, St Clair DK, et al. Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury. Toxicol Pathol, 2004,32(5): 536–547
Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest, 2005,115(3):500–508
Hare JM. Oxidative stress and apoptosis in heart failure progression. Circ Res, 2001,89(3):198–200
Boucek RJ, Jr Miracle A, Anderson M, et al. Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol, 1999,31(8):1435–1446
Lu C, Arai M, Misao Y, et al. Autologous bone marrow cell transplantation improves left ventricular function in rabbit hearts with cardiomyopathy via myocardial regeneration-unrelated mechanisms. Heart Vessels, 2006,21(3):180–187
Eldemerdash E. Evidences for prevention of nitroglycerin tolerance by carvedilol. Pharmacol Res, 2006,53(4): 380–385
Yan GX, Joshi A, Guo D, et al. Phase 2 reentry as a trigger to initiate ventricular fibrillation during early acute myocardial ischemia. Circulation, 2004,110(9): 1036–1041
Yan GX, Rials SJ, Wu Y, et al. Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization. Am J Physiol Heart Circ Physiol, 2001,281:H1968–H1975
Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis, 2007,49(5): 330–352
Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer, 2003,97(11):2869–2879
Kumar D, Lou H, Singal PK. Oxidative stress and apoptosis in heart dysfunction. Herz, 2002,27(7):662–668
Liu N, Yu R, Ruan Y, et al. Protective effect of carvedilol on abnormality of L-type calcium current induced by oxygen free radical in cardiomyocytes. J Huazhong Univ Sci Technol [Med Sci], 2004,24(5):433–436
Xiang P, Deng HY, Li K, et al. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model. Cancer Chemother Pharmacol, 2009,63(2): 343–349
Zipes DP, Wellens HJ. Sudden Cardiac Death. Circulation, 1998,98:2334–2351
Aziz EF, Javed F, Pratap B, et al. Strategies for the prevention and treatment of sudden cardiac death. Open Access Emerg Med, 2010,2:99–114
Terentyev D, Györke I, Belevych AE, et al. Redox modification of ryanodine receptors contributes to sarcoplasmic reticulum Ca2+ leak in chronic heart failure. Circ Res, 2008,103(12):1466–1472
Blayney LM, Lai FA. Ryanodine receptor-mediated arrhythmias and sudden cardiac death. Pharmacol Ther, 2009,123(2):151–177
Duan DD. A leakage leads to failure: roles of sarcoplasmic reticulum Ca2+ leak via RyR2 in heart failure progression. Hypertension, 2010,55(4):849–851
Santos DL, Moreno AJ, Leino RL, et al. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol, 2002,185(3): 218–227
Zhou Q, Xiao J, Jiang D, et al. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med, 2011,17(8):1003–1009
Zeng H, Liu X, Zhao H. Effects of carvedilol on cardiomyocyte apoptosis and gene expression in vivo after ischemia-reperfusion in rat. J Huazhong Univ Sci Technolog Med Sci, 2003,23(2):127–130
Mochizuki M, Yano M, Oda T, et al. Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol, 2007,49(16):1722–1732
Author information
Authors and Affiliations
Corresponding author
Additional information
These authors contributed equally to this work.
This project was supported by grants from the National Natural Science Foundation of China (No. 30971180) and the Natural Science Foundation of Hubei Province of China (No. 2009CDB127).
Rights and permissions
About this article
Cite this article
He, L., Xiao, J., Fu, H. et al. Effect of oxidative stress on ventricular arrhythmia in rabbits with adriamycin-induced cardiomyopathy. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 32, 334–339 (2012). https://doi.org/10.1007/s11596-012-0058-y
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-012-0058-y